Theriva Biologics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
TOVX$0.15-7.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · For the year endedDecember 31, | ||||||
| · · 2025 · · 2024 | ||||||
| Cash Flows From Operating Activities: · · · · | ||||||
| Net loss | | $(23,739) | | $(25,653) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Stock-based compensation | | 654 | | 671 | ||
| In-process research and development impairment | | — | | 1,325 | ||
| Goodwill impairment | | — | | 5,594 | ||
| Change in fair value of contingent consideration | | 9,031 | | 699 | ||
| Loss on asset disposal | | | 1 | | | — |
| Non - cash lease expense | | | 522 | | | 452 |
| Depreciation | | | 108 | | | 137 |
| Deferred research and development tax credit | | (188) | | (888) | ||
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets | | 456 | | 912 | ||
| Deposits and other assets | | | — | | | 1 |
| Accounts payable | | 69 | | 123 | ||
| Accrued expenses | | (2,277) | | 522 | ||
| Accrued employee benefits | | (744) | | (350) | ||
| Operating lease liability | | | (562) | | | (482) |
| Net Cash Used In Operating Activities | | (16,669) | | (16,937) | ||
| | | | | | ||
| Cash Flows From Investing Activities: | | | | | ||
| Purchases of property and equipment | | (35) | | (1) | ||
| Net Cash Used In Investing Activities | | | (35) | | | (1) |
| | | | | | | |
| Cash Flows From Financing Activities: | | | | | ||
| Payment of loans payable | | $(70) | | (67) | ||
| Proceeds from issuance under at - the - market offering, net of issuance cost | | | 6,833 | | | 3,603 |
| Payment of contingent consideration | | | (1,000) | | | — |
| Proceeds from issuance Common Stock and Warrants offering, net of issuance costs | | | 6,690 | | | 1,960 |
| Proceeds from warrant inducement | | | 3,942 | | | — |
| Proceeds from long term debt | | | 1,507 | | | — |
| Proceeds from issuance of common stock for warrant exercises | | | 4 | | | — |
| Tax credit receivable | | | 287 | | | — |
| Net Cash Provided By Financing Activities | | | 18,193 | | | 5,496 |
| | | | | | | |
| Effects of exchange rate changes on cash and cash equivalents | | | (92) | | | (132) |
| Net increase (decrease) in cash and cash equivalents and restricted cash | | | 1,397 | | | (11,574) |
| Cash and cash equivalents and restricted at the beginning of this period | | | 11,705 | | | 23,279 |
| Cash and cash equivalents and restricted cash at the end of this period | | $13,102 | | $11,705 | ||
| | | | | | | |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the consolidated balance sheet | | | | | | |
| Cash and cash equivalents | | | 13,056 | | | 11,609 |
| Restricted cash included in other long-term assets | | | 46 | | | 96 |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | | $13,102 | | $11,705 | ||
| | | | | | | |
| NONCASH FINANCING ACTIVITIES: | | | | | | |
| Noncash equity issuance costs and deemed dividend | | $5,880 | | | — | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.